148 related articles for article (PubMed ID: 31895417)
1. Contradictory iPledge Requirements Hinder Physician Practice and Patient Care.
Pousti BT; Mollanazar NK
JAMA Dermatol; 2020 Feb; 156(2):222. PubMed ID: 31895417
[No Abstract] [Full Text] [Related]
2. Contradictory iPledge Requirements Hinder Physician Practice and Patient Care-Reply.
Tkachenko E; Singer S; Mostaghimi A
JAMA Dermatol; 2020 Feb; 156(2):222-223. PubMed ID: 31895435
[No Abstract] [Full Text] [Related]
3. Administrative Burden of iPLEDGE Deters Isotretinoin Prescriptions: Results From a Survey of Dermatologists.
Lee G; Wolf JR; Somers KE
Cutis; 2022 Jul; 110(1):44-47. PubMed ID: 36179224
[TBL] [Abstract][Full Text] [Related]
4. A pox on your practice. iPLEDGE program scars dermatologists.
Ortolon K
Tex Med; 2006 May; 102(5):29-31. PubMed ID: 17115578
[No Abstract] [Full Text] [Related]
5. Contraceptive counseling for iPLEDGE and its burden on dermatologists.
Owens KE; Jiang SW; Nicholas MW
Arch Dermatol Res; 2024 May; 316(6):287. PubMed ID: 38805059
[TBL] [Abstract][Full Text] [Related]
6. Simplifying contraception requirements for iPLEDGE: A decision analysis.
Barbieri JS; Roe AH; Mostaghimi A
J Am Acad Dermatol; 2020 Jul; 83(1):104-108. PubMed ID: 32068040
[TBL] [Abstract][Full Text] [Related]
7. The future of iPLEDGE: We pledge for more inclusive access to isotretinoin.
Shah N; Kirkorian AY
Pediatr Dermatol; 2021 Nov; 38 Suppl 2():183-184. PubMed ID: 34184311
[No Abstract] [Full Text] [Related]
8. Isotretinoin, Patient Safety, and Patient-Centered Care-Time to Reform iPLEDGE.
Barbieri JS; Frieden IJ; Nagler AR
JAMA Dermatol; 2020 Jan; 156(1):21-22. PubMed ID: 31664426
[No Abstract] [Full Text] [Related]
9. Circumventing iPLEDGE: Circumventing ethical responsibility?
Lee KC; Bercovitch L
J Am Acad Dermatol; 2017 Dec; 77(6):1185-1187. PubMed ID: 29132856
[No Abstract] [Full Text] [Related]
10. Isotretinoin: update on controversial issues.
Prevost N; English JC
J Pediatr Adolesc Gynecol; 2013 Oct; 26(5):290-3. PubMed ID: 24147278
[TBL] [Abstract][Full Text] [Related]
11. Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era.
Charrow A; Xia FD; Lu J; Waul M; Joyce C; Mostaghimi A
PLoS One; 2019; 14(3):e0210445. PubMed ID: 30913210
[TBL] [Abstract][Full Text] [Related]
12. Can we ensure the safe use of known human teratogens?: The iPLEDGE test case.
Honein MA; Lindstrom JA; Kweder SL
Drug Saf; 2007; 30(1):5-15. PubMed ID: 17194167
[TBL] [Abstract][Full Text] [Related]
13. Family physicians and accutane.
Van Durme DJ
Am Fam Physician; 2000 Oct; 62(8):1772, 1774, 1777. PubMed ID: 11057835
[No Abstract] [Full Text] [Related]
14. Isotretinoin and iPledge: a view of results.
Maloney ME; Stone SP
J Am Acad Dermatol; 2011 Aug; 65(2):418-419. PubMed ID: 21763564
[No Abstract] [Full Text] [Related]
15. Advice on the safe introduction and continued use of isotretinoin in acne in the U.K. 2010.
Goodfield MJ; Cox NH; Bowser A; McMillan JC; Millard LG; Simpson NB; Ormerod AD
Br J Dermatol; 2010 Jun; 162(6):1172-9. PubMed ID: 21250961
[No Abstract] [Full Text] [Related]
16. Isotretinoin systemic therapy and the shadow cast upon dermatology's downtrodden hero.
Lowenstein EB; Lowenstein EJ
Clin Dermatol; 2011; 29(6):652-61. PubMed ID: 22014987
[TBL] [Abstract][Full Text] [Related]
17. We Pledge to Change iPLEDGE.
Pierson JC; Ferris LK; Schwarz EB
JAMA Dermatol; 2015 Jul; 151(7):701-2. PubMed ID: 25853235
[No Abstract] [Full Text] [Related]
18. Challenges in optimizing isotretinoin use for acne vulgaris.
McIntee TJ; Bruckner AL
JAMA Dermatol; 2013 Dec; 149(12):1398. PubMed ID: 24172999
[No Abstract] [Full Text] [Related]
19. Severe acne infantum successfully treated with isotretinoin.
Torrelo A; Pastor MA; Zambrano A
Pediatr Dermatol; 2005; 22(4):357-9. PubMed ID: 16060877
[TBL] [Abstract][Full Text] [Related]
20. Use of isotretinoin for acne vulgaris.
Merritt B; Burkhart CN; Morrell DS
Pediatr Ann; 2009 Jun; 38(6):311-20. PubMed ID: 19588674
[No Abstract] [Full Text] [Related]
[Next] [New Search]
